Skip to main content

Table 1 Description of cohort

From: Modeling of clinical phenotypes in systemic lupus erythematosus based on the platelet transcriptome and FCGR2a genotype

Category

Feature

Control (N = 18)

SLE (N = 51)

p. value

Age

mean (± sd)

42.06 (15.65)

41.14 (12.35)

0.823

Gender

Female, N (%)

18 (100)

51 (100)

1

Ethnicity

Hispanic/Latino, N (%)

4 (22.2)

23 (45.1)

0.071

Race

Asian, N (%)

1 (5.6)

12 (23.5)

0.132

Black or African American, N (%)

6 (33.3)

12 (23.5)

 

White, N (%)

10 (55.6)

27 (52.9)

 

More than one race, N (%)

1 (5.6)

0 (0)

 

Genotype

Homo ancestral, N (%)

4 (22.2)

12 (23.5)

0.993

Hetero variant, N (%)

8 (44.4)

22 (43.1)

 

Homo variant, N (%)

6 (33.3)

17 (33.3)

 

SLE Only

  

N available

N (%)

Dose (± sd)

Medication

Prednisone, N (%), mg

51

12 (23.5)

6.88 (3.04)

Hydroxychloroquine, N (%), mg

51

41 (80.4)

351.22 (84.03)

Azathioprine, N (%), mg

51

5 (9.8)

85 (33.54)

Mycophenolate mofetil N (%), mg

51

13 (25.5)

2269.23 (753.20)

Methotrexate, N (%), mg

51

2 (3.9)

13.75 (8.84)

Benlysta, N (%), IV

51

4 (7.8)

NA

SELENA SLEDAI Domains

Seizure

51

0 (0)

 

Psychosis

51

0 (0)

 

Organic brain syndrome

51

0 (0)

 

Visual disturbance

51

0 (0)

 

Cranial nerve disorder

51

0 (0)

 

Lupus headache

51

0 (0)

 

Cerebrovascular accident

51

0 (0)

 

Vasculitis

51

0 (0)

 

Arthritis

51

2 (4.1)

 

Myositis

51

0 (0)

 

Hematuria

50

4 (8.0)

 

Proteinuria

51

13 (25.5)

 

Pyuria

51

3 (5.9)

 

Rash

51

8 (15.7)

 

Alopecia

51

4 (7.8)

 

Mucosal ulcers

51

0 (0)

 

Pleurisy

51

0 (0)

 

Pericarditis

51

0 (0)

 

Low complement

51

25 (49)

 

Increased DNA binding

49

23 (46.9)

 

Fever

51

0 (0)

 

Thrombocytopenia

50

3 (6)

 

Leukopenia

51

5 (9.8)

 

SLEDAI Total

mean (± sd)

51

4.24 (4.12)

 

Predominant Disease Category

Active lupus nephritis, N (%)

47

13 (27.7)

 

Active musculoskeletal disease, N (%)

47

2 (4.3)

 

Predominately active cutaneous disease, N (%)

47

4 (8.5)

 

Predominately hematologic activity, N (%)

47

7 (14.9)

 

Clinically inactive disease and either ds-DNA or low complement N (%)

47

13 (27.7)

 

Clinically and serologically inactive disease, N (%)

47

8 (17)

 
  1. Descriptive characteristics of the SLE and control cohort. In addition, for the SLE cohort, ACR criteria, SLEDAI domains, medication usage, predominant disease category and progression status are also included. Percentages are based on available assessment data
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us